Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Interval Extension in Chronic Spontaneous Urticaria
NCT05916937Phase 4Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of omalizumab in chronic spontaneous urticaria (CSU) (2 arms). Primary endpoint: Urticaria Control Test at 36 weeks. Started Jan 2024; status: recruiting.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT05916937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05916937.